Amgen Inc.
$466
+1.15% day
A large US biotech company living on established medicines for bone loss, cancer and inflammation. Its share turns on patent expiries on those older drugs and on the pipeline meant to replace them.
Oct 30 · $466.01 · +10.6% vs the window’s open
the numbers23
| when | value | change |
|---|---|---|
| Sep 30 | $421.51 | |
| Oct 1 | $407.27 | −3.4% |
| Oct 2 | $403.04 | −1.0% |
| Oct 5 | $402.98 | 0.0% |
| Oct 6low | $402.60 | −0.1% |
| Oct 7 | $413.08 | +2.6% |
| Oct 8 | $407.44 | −1.4% |
| Oct 9 | $414.87 | +1.8% |
| Oct 12 | $417.57 | +0.7% |
| Oct 13 | $412.84 | −1.1% |
| Oct 14 | $426.11 | +3.2% |
| Oct 15 | $434.03 | +1.9% |
| Oct 16 | $432.49 | −0.4% |
| Oct 19 | $424.94 | −1.7% |
| Oct 20 | $438.94 | +3.3% |
| Oct 21 | $438.34 | −0.1% |
| Oct 22 | $447.28 | +2.0% |
| Oct 23 | $439.26 | −1.8% |
| Oct 26 | $444.63 | +1.2% |
| Oct 27 | $447.95 | +0.7% |
| Oct 28 | $451.83 | +0.9% |
| Oct 29 | $460.73 | +2.0% |
| Oct 30latest | $466.01 | +1.1% |
Lately
The FDA moved to withdraw its approval of Tavneos, Amgen's vasculitis drug, saying the approval rested on manipulated data. That news arrived after the share's climb, so it does not account for the rise, and no other report about the company's business explains it.